Haemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease: treatment with intravenous immunoglobulin. A case report.
This paper describes a case of haemophilia due to factor VIII inhibitors occurring in a 13-year-old boy suffering from an autoimmune disease. The patient had autoantibodies to factor VIII. The haemophilia was controlled by vincristine and steroids, but this regimen had to be discontinued because of side effects, whereupon the haemophilia recurred. Treatment with intravenous immunoglobulin (IgG i.v.) produced a slow rise in factor VIII, and the factor VIII inhibitors disappeared. Although factor VIII activity was raised for only a few months and factor VIII inhibitors reappeared, immunoglobulin treatment was continued and the patient remained free of clinical symptoms. The mechanism of action of treatment with IgG is discussed.
D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000743:Anemia, Hemolytic / Q000209:etiology; D001323:Autoantibodies / Q000276:immunology*; D005169:Factor VIII / Q000037:antagonists & inhibitors*; D006467:Hemophilia A / Q000150:complications / Q000628:therapy*; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000627:therapeutic use*; D007263:Infusions, Parenteral; D008297:Male; D009393:Nephritis / Q000209:etiology; D011655:Pulmonary Embolism / Q000209:etiology; D013921:Thrombocytopenia / Q000209:etiology; D014750:Vincristine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D001323:Autoantibodies; D007074:Immunoglobulin G; D014750:Vincristine; D005169:Factor VIII